Viewing Study NCT00237848



Ignite Creation Date: 2024-05-05 @ 12:04 PM
Last Modification Date: 2024-10-26 @ 9:20 AM
Study NCT ID: NCT00237848
Status: COMPLETED
Last Update Posted: 2012-06-18
First Post: 2005-09-13

Brief Title: D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
Sponsor: Yale University
Organization: Yale University

Study Overview

Official Title: D-Serine Augmentation of Cognitive Retraining in Schizophrenia
Status: COMPLETED
Status Verified Date: 2008-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will examine the effectiveness of D-serine in increasing and sustaining the benefits of cognitive retraining in people with schizophrenia
Detailed Description: This study is based on the hypothesis that by increasing NMDA receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections schizophrenic patients may derive both greater and sustained benefit from cognitive retraining

Patients with schizophrenia or schizoaffective disorder who are currently receiving antipsychotic medication will be randomly assigned in a double-blind manner to receive either D-serine 30 mgkg or placebo in addition to cognitive rehabilitation or a non-interactive placebo for 12 weeks

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
103T-363 US NIH GrantContract None httpsreporternihgovquickSearch1R01DA022495
1R01DA022495 NIH None None